| 52nd week of 2021 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20210401763 | CHLOROQUINE GEL AND PREPARATION METHOD AND APPLICATION THEREOF - A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate. | 2021-12-30 |
| 20210401764 | IMPLANTABLE DEVICES FOR DELIVERY OF BIOACTIVE AGENTS - An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent. | 2021-12-30 |
| 20210401765 | SPRAY COMPOSITIONS OF CHITOSAN FOR WOUND HEALING - The present invention relates to topical spray compositions comprising chitosan and the process for preparation thereof. The topical spray compositions comprising chitosan are used for the treating burn wounds, wounds resulting from chemical burns, wounds from physical trauma, neuropathic ulcers, pressure sores, diabetic ulcers. Further the spray compositions composition is used for treating gynaecological diseases, urogenital infections (vaginal bacteriosis, urinary tract infection and vaginitis) with good effect, safe, natural, and good biocompatibility by restoring and/or maintaining the pH of vagina. More specifically the present invention relates to topical spray compositions comprising chitosan and carbonic acid and the process for preparation thereof. | 2021-12-30 |
| 20210401766 | Method of Using Cannabinoids Encapsulated in Phospholipid Carriers for Transmucosal and Transdermal Administration - A method of administering a composition having | 2021-12-30 |
| 20210401767 | AN AQUEOUS ADHESIVE - The present invention aims to provide an aqueous adhesive which has both good moldability and strong adhesive force to the skin, and provides good feeling when used. The present invention can provide an adhesive with good shape retention performance by formulating two or more aqueous macromolecules, polyhydric alcohols, aqueous and insoluble cross-linking agents. | 2021-12-30 |
| 20210401768 | FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES - A pharmaceutical composition comprising a cannabinoid and a siloxane wherein the cannabinoid is dissolved in the composition. | 2021-12-30 |
| 20210401769 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL - The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated. | 2021-12-30 |
| 20210401770 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION - Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation. | 2021-12-30 |
| 20210401771 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY - The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). | 2021-12-30 |
| 20210401772 | COMPOSITION AND METHODS FOR STIMULATING CLEARANCE OF AMYLOID-BETA PROTEIN - The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-β protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor α (“PPARα”) to a human or veterinary subject in need of such treatment. | 2021-12-30 |
| 20210401773 | ye-COVIDICIN Botanical and Traditional Medicine to Treatment for COVID-19 - The main objective of this study was to evaluate the effects of heat, Momordicilin and antibiotics on Coronavirus. This study selected 12 individuals tested positive for COVID-19 which included two healthcare providers, one friend, a Massachusetts' family, and six family members in Florida including the inventor. All individuals were testing positive for COVID-19 excluding two individuals and inventor who didn't test. They had fever, mild headache, chest pain, cough and loss of appetite. All individuals were taking facial steaming(vapor) between 5-15 minutes for four consecutive days, a cup of Cerasee Tea with lime/lemon(Extracted-Momordicilin) three times a day for seven days and with or without any antibiotic as prescribed by their physicians. All patients felt relief immediately after taking the first dose of heat and Asosi Tea or antibiotic. All symptoms were gone in five days. After seven days, all individuals had no symptoms and re-tested. The results came negative for COVID-19. These results indicate that combination of heat, momordicilin and with or without antibiotic treat COVID-19. | 2021-12-30 |
| 20210401774 | KETAMINE PROTOCOLS AND DATA EVALUATION FOR TREATMENT-RESISTANT DEPRESSION AND TRAUMA - In an embodiment, the present disclosure pertains to a method of treatment for treatment-resistant depression or trauma. In general, the method includes administering a dose of ketamine to a subject during at least one session as defined by a ketamine-assisted psychotherapy plan. In some embodiments, the ketamine-assisted psychotherapy plan includes one or more weeks having one or more sessions. In some embodiments, the one or more weeks correspond to a phase of the ketamine-assisted psychotherapy plan. In some embodiments, the dosage of ketamine may be varied between each session of the one or more sessions. In some embodiments, the method further includes conducting at least one baseline assessment before, during, or after at least one of the one or more sessions. In some embodiments, the dose of ketamine is in a range of 0.5 mg/kg to 2.0 mg/kg. | 2021-12-30 |
| 20210401775 | A LIQUID INJECTABLE COMPOSITION - A liquid injectable composition comprising (a) at least one surfactant; (b) at least one gel strength enhancer; (c) at least one solvent; (d) optionally release retarding agent(s); (e) optionally stabilizing agent(s); (f) optionally pharmaceutical excipient(s); and (g) active pharmaceutical ingredient(s) (API) and its use in treating a subject suffering from a disease or disorder. | 2021-12-30 |
| 20210401776 | METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS - Methods of treating intractable epilepsy syndromes by administering a therapeutically effective dose of a therapeutic agent consisting essentially of a single fenfluramine enantiomer which can be either levofenfluramine or dexfenfluramine, are provided. Intractable epilepsy syndromes for which the present invention finds use include but are not limited to Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, West syndrome and refractory seizures. Also provided are methods of treating a neurodegenerative disease in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided. | 2021-12-30 |
| 20210401777 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA - Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist. | 2021-12-30 |
| 20210401778 | Onychomycosis Treatment Compositions and Methods - Compositions and methods are presented that provide substantially improved physical and pharmacological parameters for subungually administrable formulations. Most beneficially, the compositions presented herein have a viscosity and film-forming capacity that retain the liquid formulation in sufficient quantities and that help penetrate the polysaccharide matrix commonly associated with onychomycosis. In especially preferred aspects, the carrier is formulated to have a high concentration of the active pharmaceutically active agent (API), to allow migration of the formulation within the subungual space, and to reduce systemic absorption while promoting diffusion of the API into the nail plate at or above minimum inhibitory concentration into a larger treatment space. | 2021-12-30 |
| 20210401779 | PETROLATUM-BASED COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSIS - Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof. | 2021-12-30 |
| 20210401780 | Treatment of Peripheral Neuropathy Induced by Cancer Chemotherapy - Methods of treating peripheral neuropathy induced by cancer chemotherapy and/or of stimulating the regeneration of peripheral sensory nerve fibers, comprising administering topically to one or more areas of the skin capsaicin or a capsaicinoid or topical TRPV1 agonist, to a patient in need thereof, wherein the capsaicin or capsaicinoid or TRPV1 agonist is administered after the patient has received cancer chemotherapy, and wherein the patient is not currently receiving cancer chemotherapy. Related kits comprising capsaicin-containing cutaneous patches for use with said methods. | 2021-12-30 |
| 20210401781 | ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS - Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions. | 2021-12-30 |
| 20210401782 | COMPOSITION FOR PREVENTING AND TREATMENT OF STROKE - The present invention relates to a pharmaceutical composition comprising (S)-2-(((4′-trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of stroke. | 2021-12-30 |
| 20210401783 | AGENTS THAT INHIBIT NGLY1 AND METHODS OF USE THEREOF - Methods are provided for treatment of cancer cells, in a regimen comprising contacting the cancer cells with an inhibitor on NGly1, optionally in combination with a direct proteasome inhibitor. | 2021-12-30 |
| 20210401784 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE - This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same. | 2021-12-30 |
| 20210401785 | Controlled Release Dosage Form - The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABA | 2021-12-30 |
| 20210401786 | COMPOSITION FOR TREATING BURN WOUNDS - The invention provides a composition for treating a burn wound, comprising a variety of ingredients, including a fatty acid 261-639 mg, an organic substance 3.5-350 mg, a carbohydrate 0.02-60 mg, a vitamin 9-13 μg, a microelement 3.04-5.5 mg, an antibiotic 0.6-70 mg, and an amino acid 105-335 mg. The significant therapeutic effects of the invention include effectively promoting repair of a burn wound, anti-infection, inhibiting scar hyperplasia, no toxic side effect, convenient use, fast absorption, economical efficiency, etc. The invention provides patients with an efficient, economical, convenient and practical treatment for burn wounds, which greatly reduces the burden on patients, and effectively compensates for the various deficiencies of the current treatments for the non-healing burn wounds. | 2021-12-30 |
| 20210401787 | SUBSTANCES FOR TREATMENT OF FATTY LIVER-RELATED CONDITIONS - There is provided a composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammnoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate, wherein the molar ratio of A) to D) is between 250:1 and 1.5:1 and the molar ratio of A) to B) is between 16:1 and 1:4. The composition may be used in a method of treatment of a medical condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance and dyslipidemia. | 2021-12-30 |
| 20210401788 | METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSION - The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury. | 2021-12-30 |
| 20210401789 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 2021-12-30 |
| 20210401790 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA - In general, the invention relates to pharmaceutical compositions comprising 4-hydroxyatomoxetine used with a muscarinic receptor antagonist, and methods of treating sleep apnea comprising administering a muscarinic receptor antagonist and 4-hydroxyatomoxetine. The 4-hydroxyatomoxetine and muscarinic receptor antagonist are disposed in a pharmaceutically acceptable carrier. | 2021-12-30 |
| 20210401791 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY - The present invention comprises methods and compositions for reducing ethanol toxicity due to accumulation of acetaldehyde in a cell. A method comprises administering to a cell a composition comprising a compound that increases the expression, the amount of, and/or the activity of at least one member of the aldehyde dehydrogenase superfamily. | 2021-12-30 |
| 20210401792 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS - The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output. | 2021-12-30 |
| 20210401793 | TREATMENT OF CUTANEOUS DISORDERS - Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin. | 2021-12-30 |
| 20210401794 | Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep - Provided are compositions comprising cannabinol; one or more agents selected from a flavanol, an endocannabinoid, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and homodihydrocapsaicin; and, optionally, melatonin, and methods of making such compositions. The disclosed compositions can be useful in, for example, treating a sleep disorder (e.g., insomnia, seasonal affective disorder, or jet lag). The disclosed compositions can also be useful in inducing and/or promoting sleep. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2021-12-30 |
| 20210401795 | Compressible Cannabinoid Pharmaceutical Composition - A compressible pharmaceutical composition is provided as a bulk product including a cannabinoid and at least one excipient for use as an intermediate in oral formulations of cannabinoid drugs. The composition may be used in the manufacture of compressible dosage forms of cannabinoids such as tablets. The cannabinoid may be CBD or THC. The compressible excipient may be a material such as microcrystalline cellulose or lactose, or a matrix forming polymer such as a polyvinylpyrrolidone-vinyl acetate copolymer; a polyvinylcaprolactam, polyvinyl acetate, and polyethylene glycol 6000 copolymer; and an ethylene oxide and propylene oxide copolymer. Also disclosed are dry granulation processes for manufacturing the inventive composition, including slugging, roller compaction, and hot-melt extrusion. | 2021-12-30 |
| 20210401796 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER - The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder. | 2021-12-30 |
| 20210401797 | Taxane Analogs for the Treatment of Brain Cancer - Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer. | 2021-12-30 |
| 20210401798 | LIPOXIN A4 ANALOGS AND USES THEREOF - The invention relates to (S)-6-((1 R,2E,4E,8E,10S)-11-(4-fluorophenoxy)-1,10-dihydroxyundeca-2,4,8-trien-6-yn-1-yl)-1,4-dioxan-2-one (compound (1)), which is a lactone-containing analog of lipoxin A | 2021-12-30 |
| 20210401799 | METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDAC1) SUBSTANCES - A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient. | 2021-12-30 |
| 20210401800 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a). | 2021-12-30 |
| 20210401801 | METHOD FOR LONG-TERM STORAGE OF CHLOROPHYLL-CONTAINING EXTRACT - A method for long-term storage of chlorophyll which is unstable in the surrounding environment, according to an embodiment of the disclosure, includes dissolving a chlorophyll in oil having an unsaturated lipid structure to allow the chlorophyll to be included in the oil. A stabilizer employing oils having long-chain unsaturated lipid structures is used to stabilize chlorophyll. | 2021-12-30 |
| 20210401802 | PKC-DELTA-I INHIBITOR FORMULATIONS AND USES THEREOF - Provided herein are formulations that can contain an effective amount of a PKCδ inhibitor. Also provided herein are methods of inhibiting a PKCδ in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKCδ. | 2021-12-30 |
| 20210401803 | COMPOUNDS AND USES THEREOF - A pharmaceutical composition is described herein, including an antimicrobial agent and a compound having Formula A, or Formula B. Methods of using the pharmaceutical compositions to treat microbial infection are also described. | 2021-12-30 |
| 20210401804 | Use Of Carbamate Compound For Preventing, Alleviating Or Treating Myotonia - The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia. | 2021-12-30 |
| 20210401805 | Immune CB1 Activation for Obesity Therapy - Described herein are functional CB1 signaling in immune cells is necessary to dampen HFD-induced microglia/macrophage-mediated neuroinflammation and reduce obesity, targeting immune CB1 receptors constitutes a novel therapeutic modality to lessen Diet-Induced Obesity, and circumvent adverse side effects of CB1 antagonist or neuronal CB1 agonist treatment. | 2021-12-30 |
| 20210401806 | COMPOSITIONS AND METHODS FOR TREATMENT OF VAGINAL INFECTIONS - The present invention generally relates to compositions and methods for treatment and prevention of vaginal infections. More particularly, the present invention relates to compositions including creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The disclosed compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD. | 2021-12-30 |
| 20210401807 | NEW COMPOSITION COMPRISING AMORPHOUS NANOPOROUS SILICA PARTICLES - According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous silica particles, in which N-butyloxycarbonyl-3-(4-imidazol-1-yl-methylphenyl)-5-iso-butylthiophene-2-sulfonamide or a pharmaceutically-acceptable salt thereof is loaded into the pores of said silica particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter that is between about 0.1 μm and about 10 μm; and (b) a geometric standard deviation that is less than about 4. Such compositions find particular utility in the treatment of an interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis, which diseases may be treated with such compositions for example by way of pulmonary administration. | 2021-12-30 |
| 20210401808 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE- -2-CARBONYL)AMINO]PENTANOIC ACID - In one aspect, the invention relates to a compound of the structure: | 2021-12-30 |
| 20210401809 | PHARMACEUTICAL COMPOUNDS - The invention provides a compound for use in the treatment of T-Cell Acute Lymphoblastic Leukaemia (T-ALL), the compound having the formula (1): | 2021-12-30 |
| 20210401810 | Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses - The present invention relates to the novel use of antiviral compounds, which act as helicase primase inhibitors in a combination therapy with oncolytic viruses for treating tumors, cancer or neoplasia. | 2021-12-30 |
| 20210401811 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST - The present invention relates to a dosing regimen for a selective S1P | 2021-12-30 |
| 20210401812 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME - Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. | 2021-12-30 |
| 20210401813 | SOLID DISPERSION FORMS OF RIFAXIMIN - Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof. | 2021-12-30 |
| 20210401814 | MACROCYCLIC TYROSINE KINASE INHIBITOR AND USES THEREOF - The present invention belongs to the technical field of medicine, and relates to a macrocyclic tyrosine kinase inhibitor and the uses thereof. Specifically, the invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, a preparation method therefor, a pharmaceutical formulation or a pharmaceutical composition containing same, and medical uses thereof. | 2021-12-30 |
| 20210401815 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA - The present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with a drug against a disease involving gram-positive bacteria. | 2021-12-30 |
| 20210401816 | METHODS OF TREATING PANCREATIC CANCER - The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein. | 2021-12-30 |
| 20210401817 | Podloze oraz kompozycja farmaceutyczna je zawierajaca - The invention relates to a base and a pharmaceutical composition containing it for use in pharmacy. | 2021-12-30 |
| 20210401818 | SYNERGISTIC ANTI-INFLAMMATORY COMPOSITIONS - The present invention is directed to a personal composition comprising a) a strobilurin; b) a 2-pyridinol-N-oxide material wherein the ratio of a:b is from about 10:1 to about 1:20; wherein there is a synergistic anti-inflammatory/cellular stress activity. | 2021-12-30 |
| 20210401819 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR - The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material. | 2021-12-30 |
| 20210401820 | METHODS OF TREATMENT - The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days. | 2021-12-30 |
| 20210401821 | PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE - A prophylactic or therapeutic agent for an IL-31 mediated disease, said agent comprising a neurokinin B signal blocker. | 2021-12-30 |
| 20210401822 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL[-BENZAM- IDE - The present invention relates to discloses a pharmaceutical composition of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharmaceutically acceptable carrier. | 2021-12-30 |
| 20210401823 | INHIBITORS AND ANTAGONISTS OF GPR84 FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention relates to an antagonist or inhibitor of G protein-coupled receptor 84 (GPR84) for use in the treatment and/or prevention of a patient suffering from, at risk of developing, and/or being diagnosed for endometriosis, as well as methods of screening for such antagonist or inhibitor as well as methods for diagnosis. | 2021-12-30 |
| 20210401824 | Parenteral Formulations of Dopamine Agonists - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 2021-12-30 |
| 20210401825 | PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY - According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. Said compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. Said compositions and applicators may be employed in the treatment of opioid overdose in subjects. | 2021-12-30 |
| 20210401828 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-12-30 |
| 20210401829 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-12-30 |
| 20210401830 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-12-30 |
| 20210401831 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-12-30 |
| 20210401832 | PREVENTION AND/OR TREATMENT OF CONTRAST-INDUCED ACUTE KIDNEY INJURY - Methods are provided for preventing, reducing, and/or treating contrast-induced acute kidney injury which include administering an inhibitor of fatty acid oxidation to a patient in need thereof. Also provided are methods involving use of trimetazidine or pharmaceutically acceptable salts thereof for the prevention and/or treatment of contrast-induced acute kidney injury. Methods are also provided for preventing and/or treating contrast-induced acute kidney injury which include administration of one or more of trimetazidine, etomoxir, oxfenicine, perhexiline, mildronate, or ranolazine, or pharmaceutically acceptable salts of any of the preceding. | 2021-12-30 |
| 20210401833 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE - The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modified form of trimetazidine and it metabolic products in the body. The invention also provides methods of treating conditions, including angina and heart failure, using such compositions. | 2021-12-30 |
| 20210401834 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE - The invention provides pharmaceutical compositions that contain modified release formulations of modified forms of trimetazidine, such as CV-8972. The compositions include an erodible polymer, such as hydroxypropyl methylcellulose (HPMC), that allows sustained release of the modified form of trimetazidine and it metabolic products in the body. The invention also provides methods of treating conditions, including angina and heart failure, using such compositions. | 2021-12-30 |
| 20210401835 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor - Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody. | 2021-12-30 |
| 20210401836 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION - The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes. | 2021-12-30 |
| 20210401837 | TREATMENT OF CANCER - Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors. | 2021-12-30 |
| 20210401838 | IDENTIFICATION OF AGENTS DISPLAYING FUNCTIONAL ACTIVATION OF DOPAMINE D2 AND D4 RECEPTORS - A method of treating psychosis, and the underlying antipsychotic formulation. The method includes administering a therapeutically effective amount of synthetic agents that selectively recruit β-arrestin to D2 receptors and have little-to-no binding to culprit receptors associated with weight gain and Type II diabetes. The synthetic agents can include SYA16263 and SYA16264, and/or derivatives or analogs thereof. The 1-(pyridin-2-yl)piperazine moiety was found to play a significant role in recruiting β-arrestin to D2 receptors. In other embodiments, the current invention relates to synthetic agents that are selective of D4 receptors for treatment of psychosis and erectile dysfunction. The synthetic agents can include SYA27287 and/or derivatives or analogs thereof. In all embodiments, extrapyramidal side effects are eliminated or minimized. | 2021-12-30 |
| 20210401839 | EXTRUDATES COMPRISING VITAMIN B9 - The present invention relates to extrudates which comprise folic acid. To increase storage stability a solid pH buffer is added. Such extrudates have a long shelf-life even if the extrudates comprise in addition to folic acid vitamin B1 and/or vitamin B2. | 2021-12-30 |
| 20210401840 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES - The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 2021-12-30 |
| 20210401841 | METHODS OF TREATING ENDOMETRIOSIS - Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility. | 2021-12-30 |
| 20210401842 | [6R]-MTHF - an efficient folate alternative in 5-fluorouracil based chemotherapy - The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy. | 2021-12-30 |
| 20210401843 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA - Disclosed herein are compounds, compositions, and methods for treating infections by bacteria and for killing bacteria. In particular, the disclosed compounds, compositions, and methods are useful for treating infections by bacteria and for killing persister bacteria that survive antibiotic treatment and then reconstitute infections. | 2021-12-30 |
| 20210401844 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition - The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor. | 2021-12-30 |
| 20210401845 | METHODS AND COMPOSITIONS FOR KRAS INHIBITORS - In one aspect, the disclosure relates to compounds that are inhibitors of KRAS, and the disclosed compounds are allosteric inhibitors of KRAS which render them extremely useful for therapeutic intervention in a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, e.g., cancer. In various aspects, the disclosed compounds are substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs. In further aspects, the disclosed compounds can be used in methods of treating a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 2021-12-30 |
| 20210401846 | MEDICAMENT, COMPOUND, COMPOSITION AND METHOD FOR TREATING HERPES - An improved medicament, method and use for treating genital herpes in men (GHM) including a medicinal composition, which can be self-administered and maintained for a prescribed time. The medicinal composition can comprise one of an erectile dysfunction compound or medicament that can increase a genital amount of the blood flow, in combination with an anti-herpetic compound or medicament that can increase a large amount of blood flow specifically in the infected genital area. The result, of using the above medicament composition, not only achieved the disappearance of the local, genital herpetic infection, but also disappearance of the recurrence in the specific area. The medicinal composition can also include other compounds, additives, herbal extracts and/or carriers. | 2021-12-30 |
| 20210401847 | MEDICAMENTS CONTAINING RIBOFLAVIN EXHIBITING IMPROVED FLOWABILITY - Antihypertensive agents which are crystalline having a general plate shape may be difficult to formulate as they often do not exhibit good flowability properties. Addition of spray-dried riboflavin surprisingly improves flowability of these agents. | 2021-12-30 |
| 20210401848 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS - An aqueous composition includes a dihydrotriazine compound of the general formula below, | 2021-12-30 |
| 20210401849 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER - Disclosed are compositions and methods for treating benzodiazepine misuse and/or use disorder. A method of treating benzodiazepine misuse and/or use disorder includes administering to a subject in need thereof of an effective amount of a compound provides both partial modulator and antagonist effects at GABA | 2021-12-30 |
| 20210401850 | ANTIVIRAL THERAPY - The invention relates to a combination comprising (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, along with therapeutic methods administering the same. | 2021-12-30 |
| 20210401851 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER - Disclosed herein are methods of treating cancers by administration of a PAR-4 agonist. | 2021-12-30 |
| 20210401852 | TREATMENT AND PREVENTION OF PREMATURE EJACULATION (PE) - A pharmaceutical composition may include clomipramine or a pharmaceutically acceptable salt form thereof and yohimbine or a pharmaceutically acceptable salt form thereof and may be used in the treatment and prevention of premature ejaculation. The composition may contain, for example, 5 to 150 mg clomipramine, and/or, for example, 5 to 150 mg yohimbine. | 2021-12-30 |
| 20210401853 | METHODS OF TREATING NEURODEVELOPMENTAL DISORDERS - The invention relates to the treatment of neurodevelopmental disorders using an inhibitor of rho kinase. Preferred methods contemplate the treatment of infants and children. Certain embodiments involve treating a neurodevelopmental disorder is caused by defects of metabolism, including defects of amino acid transport or metabolism, acid-base balance, carbohydrate transport or metabolism, metal homeostasis, neurotransmitter metabolism, or fatty acid transport or metabolism. Methods address a variety of conditions caused by changes in the genetic material that affect the structure and/or expression of certain genes. Preferred methods treat Down syndrome, Fragile X syndrome, oligophrenin 1 deficiency, Rett syndrome, autistic disorder, Asperger's syndrome, pervasive developmental disorder not otherwise specified, and other autism spectrum disorders. | 2021-12-30 |
| 20210401854 | Pharmaceutical composition and use thereof - The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:
| 2021-12-30 |
| 20210401855 | PHARMACEUTICAL FORMULATION CONTAINING COMBINATION OF M3 ANTAGONIST-BETA-2 AGONIST AND INHALED CORTICOSTEROIDS - The present invention relates to a pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: batefenterol or a pharmaceutically acceptable salt thereof, fluticasone furoate, and a pH adjusting agent. | 2021-12-30 |
| 20210401856 | Nasal Delivery of Low-Dose Aspirin for the Treatment of Neurodegenerative and Lysosomal Storage Diseases - Provided herein are methods for delivering acetylsalicylic acid via nasal delivery for the treatment of neurodegenerative and lysosomal storage disorders, such as Alzheimer's disease and Batten disease. | 2021-12-30 |
| 20210401857 | DI-ISOPROPYL-PHOSPHINOYL-ALKANES (DAPA) COMPOUNDS AS TOPICAL AGENTS FOR THE TREATMENT OF SENSORY DISCOMFORT - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy. | 2021-12-30 |
| 20210401858 | PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS - A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation. | 2021-12-30 |
| 20210401859 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) - The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor conforming to structural Formula (I), (Ia), a species thereof, or a specified form thereof (as described herein), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., RB1 or another member of the E2F pathway). In addition, the present invention relates to methods of treating an identified patient with a compound conforming to structural Formula (I), (Ia), a species thereof, or a specified form thereof, either alone or in combination with a second therapeutic agent. In another aspect, the present invention features kits including instructions for treating a patient identified as described herein. | 2021-12-30 |
| 20210401860 | Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine - This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof. | 2021-12-30 |
| 20210401861 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF - Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said glycan therapeutics, e.g. in cancer therapy. | 2021-12-30 |
| 20210401862 | METHODS FOR MODULATING CORTICOSTERONE LEVELS IN PSYCHOLOGICALLY STRESSED INDIVIDUALS - Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods include administration of 2-fucosyl-lactose to an individual. | 2021-12-30 |
| 20210401863 | TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS - A method for treating or preventing a | 2021-12-30 |
| 20210401864 | TOPICAL ANALGESIC - Provided herein is a topical analgesic composition that includes an external analgesic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical analgesic composition. | 2021-12-30 |
